Bioelectric Science, Vol. V: Bioelectric Therapeutics — The Next Multi-Trillion-Dollar Healthcare Revolution
Introduction The global healthcare industry is at a turning point: new technologies are not only transforming patient care and outcomes,
October 2, 2025
Introduction
The global healthcare industry is at a turning point: new technologies are not only transforming patient care and outcomes, but also how therapies are discovered, deployed, and paid for (1,2,3). Near the center of this transformation is bioelectric medicine, a multidisciplinary field that leverages the body’s own electrical language to treat chronic diseases, promote healing, and control pain, inflammation, infection, and even cancer (4,5,6). Forecasts suggest bioelectric approaches could reshape markets worth trillions of dollars, delivering smarter, more sustainable solutions for patients and systems alike (2,7,
.
Electrome is positioned at the leading edge of this revolution, combining rapid discovery, scalable hardware, and AI-driven analytics to create first-in-class therapies and a development model built for the future.
What Is Bioelectric Medicine and Why Now?
Bioelectric medicine involves the targeted modulation of the body’s natural electrical pathways to achieve clinical effects, often through precision devices that sense and stimulate neural circuits, muscles, or tissue microenvironments (4,5). Whereas pharmaceuticals work by introducing chemicals that can have broad, systemic effects and frequent side effects, bioelectric approaches enable localized, quickly reversible, and highly tailored interventions (1,4).
Key drivers accelerating this field include:
Chronic and lifestyle diseases remain poorly managed with traditional drugs.
The opioid crisis and increasing demand for non-addictive pain management.
Patient demand for non-invasive, personalized, and home-based therapies (5).
The rapid maturation of digital health, remote monitoring, and AI-powered diagnostics.
A favorable regulatory climate and significant investment from leading pharmaceutical and device manufacturers (4,8,9).
How Bioelectric Platforms Work: From Bench to Bedside
Traditional pharmaceutical R&D cycles often take a decade or longer. By contrast, bioelectric therapeutics, especially those built on modular and scalable hardware, can be iterated more like digital technology, with swift integration of clinical feedback, regulatory enhancements, and next-generation engineering (4,9).
Electrome’s platform encompasses:
Knowledge graph: An AI-driven database mapping every tested waveform, clinical outcome, and biomarker association to algorithmically guide the discovery and optimization of new therapies (5).
Scalable hardware: Modular, interchangeable components allow for precision tailoring to specific physiological targets, disease states, and patient needs, while ensuring streamlined manufacturing and regulatory clearance (5).
Personalization tools: Biosensors, mobile health integration, and remote monitoring support individualized protocols, the right stimulation, at the right dose, at the right time (4,5).
Pipeline and revenue: Electrome’s first therapy, targeting pain and inflammation, is already cleared for market launch with additional indications under development (5).
Closing In on Major Disease Areas
Pain and Inflammation
Bioelectric platforms already demonstrate robust efficacy in chronic pain and inflammatory disorders. For example, Transcutaneous Electrical Nerve Stimulation (TENS), spinal cord stimulators, and vagal nerve modulators are proven alternatives or adjuncts to pharmaceuticals, often minimizing or entirely replacing the need for opioids (4,6,9). Precision stimulation tools can not only block maladaptive pain signals but shift immune networks from inflammatory to healing profiles (3,6).
Chief Operating Officer Dr. Wanni Davis highlights the vision behind Electrome’s innovation in this therapeutic area:
“Understanding how bioelectric properties influence regeneration can help us develop more effective treatment protocols. By unlocking the body’s regenerative capacity through electrical signals, we provide innovative solutions to previously hard-to-treat conditions”.
Infection and Wound Healing
New bioelectric dressings, feedback-controlled wound patches, and implantables demonstrate accelerated healing, reduced infection, and better tissue integration (4,5,6). In difficult cases, chronic ulcers, burns, and post-surgical wounds, these modalities are leading to more rapid closure and lower rates of recurrence, which profoundly affect healthcare costs and patient lives (4,10,11).
Cancer
Emerging research shows that unique electrical properties of tumors can be exploited for non-invasive treatment, Tumor Treating Fields (TTFields), modulated hyperthermia, and novel radiofrequency protocols all offer increased efficacy with reduced toxicity (6,12,13). Electrome’s development teams are also advancing personalized electric field-based cancer therapies in collaboration with top oncology centers (12).
Neurology and Beyond
Neuromodulation for epilepsy, migration disorder, and depression has long been established. Next-gen closed-loop devices from companies like Electrome employ real-time sensing and “sense-and-respond” feedback, adapting therapy moment by moment based on patient activity, seizure risk, or even mood (4,5,9).
How Electrome Accelerates Discovery and Impact
By uniting in-house algorithmic discovery, scalable engineering, and a deep bench of translational and regulatory expertise, Electrome is shaping the future of medicine itself (5). CTO Dr. Erik Nilsen explains the company’s unique edge:
“We are developing technologies that provide precise control over electric signaling in cells, offering new opportunities to treat chronic pain, inflammation, and other debilitating conditions” (4).
This approach, validated by the Electrome Knowledge Graph and real-world clinical data, catapults the entire field forward. Faster device iteration, lower cost, and superior matching of patient to protocol translates into healthier outcomes and system-scale sustainability.
Economic and Social Promise
The costs of chronic pain, wounds, inflammation, and cancer in high- and low-income countries are staggering (7,8,9). Electrome’s platform allows for wide-reaching, curated, and highly scalable deployment across diverse settings. Telemedicine integration further broadens access, empowering local clinicians with global best practices in real time (5).
Analysts forecast that the global bioelectric medicine market could exceed $40 billion by 2032, and the broader economic impact, including improved productivity and reduced long-term disability, may be far larger (7, . With products positioned for both premium healthcare systems and cost-effective community deployment, Electrome is poised for international leadership.
Pathways Forward: Research, Partnerships, and Policy
Electrome invests significantly in partnerships that drive open-source toolkits, cross-provider data sharing, and clinician training in bioelectric solutions (5). Ongoing regulatory outreach ensures each product meets rising global expectations for safety, interoperability, and data stewardship.
<<<<<<<< As payer and policymaker incentives align with digital health expansion and value-based care, Electrome stands ready to scale new solutions, from its flagship pain and wound programs into chronic disease, cancer, transplantation, trauma, and more (5,12). >>>>>>>>
Conclusion
A new era in medicine dawns as <<<<<<< bioelectric therapeutics>>>>>>> move from visionary research to real-world impact, altering the clinical and economic landscape across continents (2,5,7). By combining discovery engines, modular platforms, and a commitment to rapid translation, <<<<<<<< Electrome sets the pace for a healthcare revolution that centers on biology’s original language, electricity, one patient, provider, and system at a time.>>>>>>>
References
Next-Generation Bioelectric Medicine: Harnessing the Therapeutic Potential. Front Neurol. 2020;11:616529. https://pmc.ncbi.nlm.nih.gov/articles/PMC8370382/
Electrome | Precision Bioelectric Therapeutics for Pain, Infection, and Cancer. https://electrome.io
Bioelectronic Medicine: a multidisciplinary roadmap from biophysics to patient care. Front Integr Neurosci. 2024;18:1321872. https://www.frontiersin.org/journals/integrat...21872/full
8 Companies Developing Bioelectronic Devices. Nanalyze. https://www.nanalyze.com/2021/03/fda-approved...c-devices/
Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion Globally by 2032. Allied Market Research. 2024. https://www.prnewswire.com/news-releases/elec...24096.html
Grand View Research. Bioelectric Medicine Market Size And Share Report, 2030.
The rise of bioelectric medicine sparks interest among researchers. PNAS. 2019;116(49):24379-24381. https://www.pnas.org/doi/10.1073/pnas.1919040116
Bioelectric Medicine Companies | Market Research Future. https://www.marketresearchfuture.com/reports/.../companies
Bioelectronic Medicine: The Next New Frontier. YouTube. Northwell Health. 2024. https://www.youtube.com/watch?v=9SskZWo3SJY
Bioelectronic Therapy for Treating Painful Conditions. WebMD. 2024. https://www.webmd.com/pain-management/bioelectric-therapy
Bioelectromagnetism for Cancer Treatment—Modulated Electro-Hyperthermia. Cancers. 2025;17(3):927. https://pmc.ncbi.nlm.nih.gov/articles/PMC11941104/
Bioelectronic medicines: Therapeutic potential and advancements in next-generation cancer therapy. J Control Release. 2022;349:440-456. https://www.sciencedirect.com/science/article...9X22001330
Nanotechnology and Cancer Bioelectricity: Bridging the Gap. Adv Sci (Weinh). 2023;e2304110. https://onlinelibrary.wiley.com/doi/full/10.1....202304110
Vol. V
Introduction The global healthcare industry is at a turning point: new technologies are not only transforming patient care and outcomes,
October 2, 2025
Introduction
The global healthcare industry is at a turning point: new technologies are not only transforming patient care and outcomes, but also how therapies are discovered, deployed, and paid for (1,2,3). Near the center of this transformation is bioelectric medicine, a multidisciplinary field that leverages the body’s own electrical language to treat chronic diseases, promote healing, and control pain, inflammation, infection, and even cancer (4,5,6). Forecasts suggest bioelectric approaches could reshape markets worth trillions of dollars, delivering smarter, more sustainable solutions for patients and systems alike (2,7,
. Electrome is positioned at the leading edge of this revolution, combining rapid discovery, scalable hardware, and AI-driven analytics to create first-in-class therapies and a development model built for the future.
What Is Bioelectric Medicine and Why Now?
Bioelectric medicine involves the targeted modulation of the body’s natural electrical pathways to achieve clinical effects, often through precision devices that sense and stimulate neural circuits, muscles, or tissue microenvironments (4,5). Whereas pharmaceuticals work by introducing chemicals that can have broad, systemic effects and frequent side effects, bioelectric approaches enable localized, quickly reversible, and highly tailored interventions (1,4).
Key drivers accelerating this field include:
Chronic and lifestyle diseases remain poorly managed with traditional drugs.
The opioid crisis and increasing demand for non-addictive pain management.
Patient demand for non-invasive, personalized, and home-based therapies (5).
The rapid maturation of digital health, remote monitoring, and AI-powered diagnostics.
A favorable regulatory climate and significant investment from leading pharmaceutical and device manufacturers (4,8,9).
How Bioelectric Platforms Work: From Bench to Bedside
Traditional pharmaceutical R&D cycles often take a decade or longer. By contrast, bioelectric therapeutics, especially those built on modular and scalable hardware, can be iterated more like digital technology, with swift integration of clinical feedback, regulatory enhancements, and next-generation engineering (4,9).
Electrome’s platform encompasses:
Knowledge graph: An AI-driven database mapping every tested waveform, clinical outcome, and biomarker association to algorithmically guide the discovery and optimization of new therapies (5).
Scalable hardware: Modular, interchangeable components allow for precision tailoring to specific physiological targets, disease states, and patient needs, while ensuring streamlined manufacturing and regulatory clearance (5).
Personalization tools: Biosensors, mobile health integration, and remote monitoring support individualized protocols, the right stimulation, at the right dose, at the right time (4,5).
Pipeline and revenue: Electrome’s first therapy, targeting pain and inflammation, is already cleared for market launch with additional indications under development (5).
Closing In on Major Disease Areas
Pain and Inflammation
Bioelectric platforms already demonstrate robust efficacy in chronic pain and inflammatory disorders. For example, Transcutaneous Electrical Nerve Stimulation (TENS), spinal cord stimulators, and vagal nerve modulators are proven alternatives or adjuncts to pharmaceuticals, often minimizing or entirely replacing the need for opioids (4,6,9). Precision stimulation tools can not only block maladaptive pain signals but shift immune networks from inflammatory to healing profiles (3,6).
Chief Operating Officer Dr. Wanni Davis highlights the vision behind Electrome’s innovation in this therapeutic area:
“Understanding how bioelectric properties influence regeneration can help us develop more effective treatment protocols. By unlocking the body’s regenerative capacity through electrical signals, we provide innovative solutions to previously hard-to-treat conditions”.
Infection and Wound Healing
New bioelectric dressings, feedback-controlled wound patches, and implantables demonstrate accelerated healing, reduced infection, and better tissue integration (4,5,6). In difficult cases, chronic ulcers, burns, and post-surgical wounds, these modalities are leading to more rapid closure and lower rates of recurrence, which profoundly affect healthcare costs and patient lives (4,10,11).
Cancer
Emerging research shows that unique electrical properties of tumors can be exploited for non-invasive treatment, Tumor Treating Fields (TTFields), modulated hyperthermia, and novel radiofrequency protocols all offer increased efficacy with reduced toxicity (6,12,13). Electrome’s development teams are also advancing personalized electric field-based cancer therapies in collaboration with top oncology centers (12).
Neurology and Beyond
Neuromodulation for epilepsy, migration disorder, and depression has long been established. Next-gen closed-loop devices from companies like Electrome employ real-time sensing and “sense-and-respond” feedback, adapting therapy moment by moment based on patient activity, seizure risk, or even mood (4,5,9).
How Electrome Accelerates Discovery and Impact
By uniting in-house algorithmic discovery, scalable engineering, and a deep bench of translational and regulatory expertise, Electrome is shaping the future of medicine itself (5). CTO Dr. Erik Nilsen explains the company’s unique edge:
“We are developing technologies that provide precise control over electric signaling in cells, offering new opportunities to treat chronic pain, inflammation, and other debilitating conditions” (4).
This approach, validated by the Electrome Knowledge Graph and real-world clinical data, catapults the entire field forward. Faster device iteration, lower cost, and superior matching of patient to protocol translates into healthier outcomes and system-scale sustainability.
Economic and Social Promise
The costs of chronic pain, wounds, inflammation, and cancer in high- and low-income countries are staggering (7,8,9). Electrome’s platform allows for wide-reaching, curated, and highly scalable deployment across diverse settings. Telemedicine integration further broadens access, empowering local clinicians with global best practices in real time (5).
Analysts forecast that the global bioelectric medicine market could exceed $40 billion by 2032, and the broader economic impact, including improved productivity and reduced long-term disability, may be far larger (7,
. With products positioned for both premium healthcare systems and cost-effective community deployment, Electrome is poised for international leadership. Pathways Forward: Research, Partnerships, and Policy
Electrome invests significantly in partnerships that drive open-source toolkits, cross-provider data sharing, and clinician training in bioelectric solutions (5). Ongoing regulatory outreach ensures each product meets rising global expectations for safety, interoperability, and data stewardship.
<<<<<<<< As payer and policymaker incentives align with digital health expansion and value-based care, Electrome stands ready to scale new solutions, from its flagship pain and wound programs into chronic disease, cancer, transplantation, trauma, and more (5,12). >>>>>>>>
Conclusion
A new era in medicine dawns as <<<<<<< bioelectric therapeutics>>>>>>> move from visionary research to real-world impact, altering the clinical and economic landscape across continents (2,5,7). By combining discovery engines, modular platforms, and a commitment to rapid translation, <<<<<<<< Electrome sets the pace for a healthcare revolution that centers on biology’s original language, electricity, one patient, provider, and system at a time.>>>>>>>
References
Next-Generation Bioelectric Medicine: Harnessing the Therapeutic Potential. Front Neurol. 2020;11:616529. https://pmc.ncbi.nlm.nih.gov/articles/PMC8370382/
Electrome | Precision Bioelectric Therapeutics for Pain, Infection, and Cancer. https://electrome.io
Bioelectronic Medicine: a multidisciplinary roadmap from biophysics to patient care. Front Integr Neurosci. 2024;18:1321872. https://www.frontiersin.org/journals/integrat...21872/full
8 Companies Developing Bioelectronic Devices. Nanalyze. https://www.nanalyze.com/2021/03/fda-approved...c-devices/
Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion Globally by 2032. Allied Market Research. 2024. https://www.prnewswire.com/news-releases/elec...24096.html
Grand View Research. Bioelectric Medicine Market Size And Share Report, 2030.
The rise of bioelectric medicine sparks interest among researchers. PNAS. 2019;116(49):24379-24381. https://www.pnas.org/doi/10.1073/pnas.1919040116
Bioelectric Medicine Companies | Market Research Future. https://www.marketresearchfuture.com/reports/.../companies
Bioelectronic Medicine: The Next New Frontier. YouTube. Northwell Health. 2024. https://www.youtube.com/watch?v=9SskZWo3SJY
Bioelectronic Therapy for Treating Painful Conditions. WebMD. 2024. https://www.webmd.com/pain-management/bioelectric-therapy
Bioelectromagnetism for Cancer Treatment—Modulated Electro-Hyperthermia. Cancers. 2025;17(3):927. https://pmc.ncbi.nlm.nih.gov/articles/PMC11941104/
Bioelectronic medicines: Therapeutic potential and advancements in next-generation cancer therapy. J Control Release. 2022;349:440-456. https://www.sciencedirect.com/science/article...9X22001330
Nanotechnology and Cancer Bioelectricity: Bridging the Gap. Adv Sci (Weinh). 2023;e2304110. https://onlinelibrary.wiley.com/doi/full/10.1....202304110
Vol. V
2
